Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| DiaMedica Therapeutics Inc.DMAC · Entity 5813 | Chief Commercial Officer | June 01, 2024 | June 03, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
DiaMedica Therapeutics Inc.
Report date June 01, 2024 · Filed June 03, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.90 · Expires 2034-05-31 | Direct | 15,000 |
Reported balance
After 2024-06-01 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2024-06-01 · Grant · Acquired 15,000 · Balance 15,000 F1: Vests with respect to 25% of the underlying common shares on June 1, 2025 and with respect to the remaining 75% of the underlying common shares vesting quarterly over the following three years commencing on September 1, 2025. |
| Voting Common Shares, no par value per shareSEC Table I · non-derivative | Direct | 2,800 |
Reported balance
Holding disclosure · report date 2024-06-01 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 2,800 |
Filing footnotes · ownership attribution and instrument terms
F1: Vests with respect to 25% of the underlying common shares on June 1, 2025 and with respect to the remaining 75% of the underlying common shares vesting quarterly over the following three years commencing on September 1, 2025.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 01, 2024 Filed Jun 3, 2024 20:58 UTC | DiaMedica Therapeutics Inc. DMAC · Entity 5813 | GrantStock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $2.90 | $0.00 |
DisclosureSEC source: 0001235802-24-000051 · primary_doc.xml · derivative · entry 2 Cundari Dominic R · CIK 0001907057 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Shares · 15,000 shares Expires 2034-05-31 F1 · derivative.exercise_date: Vests with respect to 25% of the underlying common shares on June 1, 2025 and with respect to the remaining 75% of the underlying common shares vesting quarterly over the following three years commencing on September 1, 2025. Read SEC document |
| June 01, 2023 Filed Jun 2, 2023 21:01 UTC | DiaMedica Therapeutics Inc. DMAC · Entity 5813 | GrantStock Option (right to buy) · Derivative | 27,000 | $0.00 Strike: $2.73 | $0.00 |
DisclosureSEC source: 0001235802-23-000064 · primary_doc.xml · derivative · entry 2 Cundari Dominic R · CIK 0001907057 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,000 Underlying: Common Shares · 27,000 shares Expires 2033-05-31 F1 · derivative.exercise_date: Vests with respect to 25% of the underlying common shares on June 1, 2024 and with respect to the remaining 75% of the underlying common shares vesting quarterly over the following three years commencing on September 1, 2024. Read SEC document |
| February 01, 2022 Filed Feb 2, 2022 21:45 UTC | DiaMedica Therapeutics Inc. DMAC · Entity 5813 | GrantStock Option (right to buy) · Derivative | 40,000 | $0.00 Strike: $2.90 | $0.00 |
DisclosureSEC source: 0001235802-22-000024 · primary_doc.xml · derivative · entry 3 Cundari Dominic R · CIK 0001907057 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Shares · 40,000 shares Expires 2032-02-01 F2 · derivative.exercise_date: This option vests with respect to 10,000 common shares on May 1, 2022 and with respect to the remaining 75% of the common shares in three nearly equal installments on each of August 1, 2022, November 1, 2022 and February 1, 2023. Read SEC document |
| February 01, 2022 Filed Feb 2, 2022 21:45 UTC | DiaMedica Therapeutics Inc. DMAC · Entity 5813 | GrantStock Option (right to buy) · Derivative | 125,000 | $0.00 Strike: $2.90 | $0.00 |
DisclosureSEC source: 0001235802-22-000024 · primary_doc.xml · derivative · entry 2 Cundari Dominic R · CIK 0001907057 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,000 Underlying: Common Shares · 125,000 shares Expires 2032-02-01 F1 · derivative.exercise_date: This option vests with respect to 31,250 common shares on February 1, 2023 and with respect to the remaining 75% of the common shares in 36 nearly equal monthly installments commencing one month after the one-year anniversary of the grant date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.